SeqLL, Inc. (SQL): Price and Financial Metrics
SQL Price/Volume Stats
|Current price||$15.36||52-week high||$96.00|
|Prev. close||$14.31||52-week low||$9.21|
|Day high||$18.04||Avg. volume||58,145|
|50-day MA||$14.80||Dividend yield||N/A|
|200-day MA||$17.94||Market Cap||5.33M|
SQL Stock Price Chart Interactive Chart >
SQL Stock Summary
- SQL has a market capitalization of $5,151,847 -- more than approximately only 2.27% of US stocks.
- With a price/sales ratio of 165.25, SEQLL INC has a higher such ratio than 98.05% of stocks in our set.
- Revenue growth over the past 12 months for SEQLL INC comes in at -84.15%, a number that bests just 1.87% of the US stocks we're tracking.
- Stocks that are quantitatively similar to SQL, based on their financial statements, market capitalization, and price volatility, are CVAC, AYRO, ACLS, SIGA, and VNDA.
- To check out SEQLL INC's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001605888.
SQL Valuation Summary
- SQL's price/sales ratio is 164.5; this is 7733.33% higher than that of the median Healthcare stock.
- SQL's price/earnings ratio has moved up 46.6 over the prior 23 months.
Below are key valuation metrics over time for SQL.
SeqLL, Inc. (SQL) Company Bio
SeqLL Inc. operates as a life sciences instrumentation and research services company worldwide. It designs, develops, and manufactures genetic analysis technologies; and offers true single molecule sequencing (tSMS) platform that assists researchers to develop research, diagnostics, and therapeutics applications. The company also provides RNA sequencing services and instruments, which include Direct RNA Sequencing, a genetic testing and mapping service that captures polyadenylated RNA directly without conversion to cDNA; tSMS formalin fixed paraffin embedded (FFPE) service to analyze damaged or fragmented nucleic acids from formalin fixed paraffin embedded samples and other sources; micro RNA sequencing; and custom sequencing, and mapping and testing services, as well as gene expression studies, FFPE RNA Sequencing, biomarker discovery, fusion detection, rare mutation detection, transcriptome profiling, and cap analysis gene expression services. In addition, it offers DNA sequencing services and instruments, such as shotgun DNA sequencing, direct capture sequencing, cell free DNA sequencing, FFPE DNA sequencing, ancient DNA sequencing, and targeted sequencing, as well as microbiome studies, biomarker discovery, and tumor profiling services. Further, the company provides bioinformatics services comprising data processing, biomarkers research, pathway analysis, and gene expression analysis services, as well as undertakes various custom projects. It has a collaboration agreement with Bernstein Laboratory, Ting Laboratory, The Jackson Laboratory for Genomic Medicine, Weizmann Institute of Science, True Bearing Diagnostics, Inc., and Tetracore, Inc. The company serves academic and government institutions, hospitals and medical centers, pharmaceutical and biotechnology companies, and non-profit research organizations. SeqLL Inc. was founded in 2013 and is based in Woburn, Massachusetts.
SQL Latest News Stream
|Loading, please wait...|
SQL Latest Social Stream
View Full SQL Social Stream
Latest SQL News From Around the Web
Below are the latest news stories about SEQLL INC that investors may wish to consider to help them evaluate SQL as an investment opportunity.
BILLERICA, Mass., Sept. 15, 2023 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (Nasdaq: SQL, SQLLW), announced today that its board of directors has set September 26, 2023 as the record date for its special stock dividend and cash dividend to be made to the holders of its common stock pursuant to the terms of the Agreement and Plan of Reorganization dated as of May 29, 2023, as amended (the “Merger Agreement”), by and among the Company, SeqLL Merger LLC, Atlantic Acquisition Corp., A
BILLERICA, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (Nasdaq: SQL, SQLLW), a technology company providing life sciences instrumentation and research services, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-40. The reverse stock split will become effective at 11:59 p.m. Eastern Time, on August 30, 2023. The Company's common stock will begin trading on a post-split basis at the market ope
In this piece, we will take a look at ten special situation penny stocks to consider. If you want to skip our analysis of the stock market and the economy, head on over to 5 Special Situation Penny Stocks to Consider. For the stock market these days, it’s nothing but cheers. June has proven to […]
SeqLL Inc. Enters into a Definitive Merger Agreement with Lyneer Staffing Solutions and Atlantic Acquisition Corp.
BILLERICA, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (Nasdaq: SQL, SQLLW), a technology company providing life sciences instrumentation and research services, today announced that it has entered into a definitive merger agreement (the “Merger Agreement”) with Lyneer Investments, LLC (“Lyneer”), the indirect parent company of Lyneer Staffing Solutions, LLC and Atlantic Acquisition Corp. (“Atlantic”), and related parties, pursuant to which Lyneer will become a w
It's time for a dive into the biggest pre-market stock movers as we check out all of the latest news for Wednesday morning!
SQL Price Returns